The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "Biologics"

Search results for: Biologics

Clinical Guidelines for Sjögren’s Syndrome Focus on Biologics, Fatigue, Inflammatory Musculoskeletal Pain

June 15, 2017 • By Kurt Ullman

The first clinical practice guidelines for Sjögren’s syndrome have been released, the culmination of an initiative by the Sjögren’s Syndrome Foundation.1 These standard-of-care recommendations are intended to provide consistency in practice patterns, inform coverage and reimbursement policies, lead to the design and implementation of educational programs, highlight the needs for future research and fill a… [Read More]

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: biologic, Clinical, drug therapy, fatigue, guideline, inflammatory musculoskeletal disease, Pain, patient care, recommendation, Rheumatic Disease, Sjögren's syndrome, Sjögren's Syndrome Foundation, Treatment

Sanofi to Invest Further in Biologics

June 14, 2017 • By Matthias Blamont

PARIS (Reuters)—Sanofi announced plans to invest 600 million euros ($673 million) annually over the next two to three years in the field of biologics production, an area of strong growth potential. In contrast to most drugs that are chemically synthesized, many biologics are produced using living cells. They are seen as a promising answer in… [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biologics, Sanofi

U.S. Top Court Debates Making Copycat Biologics Available Sooner

April 26, 2017 • By Andrew Chung

WASHINGTON (Reuters)—U.S. Supreme Court justices on Wednesday struggled over whether to speed up the time it takes to bring to the market copycat versions of biologic drugs, expensive medicines that can generate billions of dollars in sales for drug makers. The nine justices heard arguments in an appeal by Novartis AG of a lower court… [Read More]

Filed Under: Drug Updates, Professional Topics Tagged With: Amgen Inc, Copycat Biologics, filgrastim, Neupogen, Novartis AG, U.S. Supreme Court

Recommendations for Sjögren’s Syndrome: How to Address Biologics & Musculoskeletal Pain

April 2, 2017 • By Arthritis Care & Research

The clinical practice guidelines for managing Sjögren’s syndrome, developed by the Sjögren’s Syndrome Foundation with the ACR, were designed to improve quality and consistency of care. In total, 19 recommendations were agreed on, which include managing the rheumatic and systemic aspects of the disease. Recommendations include a decision tree for the use of DMARDs for inflammatory musculoskeletal pain, use of self-care measures and exercise to reduce fatigue, and the use of rituximab in selected clinical settings for oral and ocular dryness…... [Read More]

Filed Under: Conditions Tagged With: Arthritis Care & Research, Clinical Practice Guidelines, fatigue, Musculoskeletal, rituximab, sicca, Sjögren's syndrome

When Starting Biologics for RA, Disease Severity Predicts Likelihood of Remission

March 22, 2017 • By Reuters Staff

NEW YORK (Reuters Health)—After starting biologic therapy for rheumatoid arthritis (RA), patients with higher disease activity at baseline achieved greater improvements in measures of disease activity than those with lower levels of disease, but they were less likely to achieve remission or even low disease activity, according to a new real world analysis of registry data…. [Read More]

Filed Under: Biologics & Biosimilars, Conditions, Rheumatoid Arthritis Tagged With: biologic drugs, biologic therapy, Remission, Rheumatoid Arthritis (RA)

Tips, Resources to Help Rheumatologists Educate Patients on Biologics and Biosimilars

February 15, 2017 • By Vanessa Caceres

Syda Productions/shutterstock.com

Rheumatologists are accustomed to educating patients about medications—but biologic medications require some additional time and discussion. “Biologics are inherently more complex [than other medications], and there are multiple issues to consider before initiating treatment,” says K. “Kwas” Huston, MD, The Center for Rheumatic Disease, Kansas City, Mo. “This includes the patient’s disease activity, prior medications… [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates, Practice Management Tagged With: Biologics, Drugs, patient care, Practice Management, Quality, rheumatologist, rheumatology, Safety, therapy, Treatment

Do RA Patients in Clinical Trials for Biologics Represent the Average?

October 4, 2016 • By Arthritis Care & Research

It’s estimated that a majority of patients with rheumatoid arthritis (RA) have been exposed to biologic treatments. However, the randomized controlled trials demonstrating the safety and efficacy of these biologic agents have strict participant eligibility requirements. New research has examined the requirements of 30 trials for biologics and applied those standards to two large clinical cohorts. The result: A majority of these RA patients did not satisfy the criteria…... [Read More]

Filed Under: Biologics & Biosimilars Tagged With: Biologics, Biologics & Biosimilars, clinical trials, non-TNF biologics, randomized controlled trial, TNF inhibitors

New Research into Rheumatoid Arthritis, Gout Includes Updates on Methotrexate, Biologics, Ultrasound

September 8, 2016 • By Thomas R. Collins

LONDON—From optimizing responses to methotrexate, to the efficacy of biologics, to the need for imaging in assessing remission, the literature, as ever, has been lively with explorations of pressing topics in the treatment and management of rheumatoid arthritis. Josef Smolen, MD, chair of rheumatology at the Medical University of Vienna, reviewed many of the highlights… [Read More]

Filed Under: Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: Biologics, drug update, EULAR 2016, European League Against Rheumatism, Gout, Methotrexate, patient care, Research, Rheumatoid arthritis, rheumatologist, Treatment, Ultrasound

Arthritis Patients Lack Knowledge about Safe Use of Biologics

June 15, 2016 • By Will Boggs, MD

NEW YORK (Reuters Health)—Many patients with arthritis lack the knowledge to use their biologic treatments safely, researchers from France report. “Some patients are at risk of poorly managing their biologic therapy, especially patients living alone, in a large city, patients with low education level, or (patients who are) unemployed,” Dr. Anne-Christine Rat from CHU de… [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Arthritis, Biologics, patient education

Newer Biologics for RA on Par with TNF-Inhibitors for CV Risk

February 2, 2016 • By Laura Newman

NEW YORK (Reuters Health)—The newer disease-modifying drugs for rheumatoid arthritis appear to offer the same or even better cardiovascular (CV) protection than older tumor necrosis factor (TNF) inhibitors, hints a large study. “We really haven’t had a good understanding on where the non-TNF biologics and CV risk stand,” Dr. Jeffrey R. Curtis of the University… [Read More]

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates, Rheumatoid Arthritis Tagged With: cardiovascular, disease-modifying antirheumatic drugs, Myocardial infarction, non-TNF biologics, Rheumatoid Arthritis (RA), TNF, tumor necrosis factor

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 57
  • Next Page »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.